Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
- Conditions
- HIV Infections
- Registration Number
- NCT00062660
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- APPROVED_FOR_MARKETING
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (146)
1182.58.31
🇺🇸Scottsdale, Arizona, United States
1182.58.29
🇺🇸Los Angeles, California, United States
1182.58.34 Campus Code 696446
🇺🇸Los Angeles, California, United States
1182.58.42 Synergy Hematology/Oncology
🇺🇸Los Angeles, California, United States
1182.58.43
🇺🇸Los Angeles, California, United States
1182.58.03
🇺🇸San Francisco, California, United States
1182.58.33 Kaiser Permanente Medical Center, Clinical Trials Unit
🇺🇸San Francisco, California, United States
1182.58.37 AIDS Health Care Foundation
🇺🇸Los Angeles, Connecticut, United States
1182.58.41 Circle Medical, LLC
🇺🇸Norwalk, Connecticut, United States
1182.58.28
🇺🇸Washington, District of Columbia, United States
Scroll for more (136 remaining)1182.58.31🇺🇸Scottsdale, Arizona, United States